TriangleNivolumab (NCT03258567)
Nivolumab trial for Epstein-Barr Virus Infections (NCT03258567). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged twelve or older with selected EBV-positive lymphoproliferative disorders or B-cell non-Hodgkin lymphomas. Lymphoma requires relapse after anthracycline/rituximab treatment or ineligibility for it; lymphoproliferative disorders may be untreated. Adolescents have weight criteria.
The idea: block PD-1 with nivolumab to release an immune checkpoint. The open arm gives 480-milligram infusions every four weeks, for up to two years if benefiting and tolerating treatment. The two-week schedule closed. Researchers measure response; tissue is required.
This phase 2 study plans 40 patients. Christopher Melani leads at NIH’s recruiting Bethesda site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.